396 related articles for article (PubMed ID: 22057509)
41. How I treat childhood CML.
Andolina JR; Neudorf SM; Corey SJ
Blood; 2012 Feb; 119(8):1821-30. PubMed ID: 22210880
[TBL] [Abstract][Full Text] [Related]
42. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
Huang XJ; Xu LP; Liu KY; Liu DH; Chen H; Liu YR; Chen YH; Han W; Wang Y
Biol Blood Marrow Transplant; 2011 May; 17(5):649-56. PubMed ID: 20691800
[TBL] [Abstract][Full Text] [Related]
43. Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.
Xu Y; Wahner AE; Nguyen PL
Arch Pathol Lab Med; 2004 Sep; 128(9):980-5. PubMed ID: 15338554
[TBL] [Abstract][Full Text] [Related]
44. Philadelphia-chromosome-positive T-lymphoblastic leukemia: acute leukemia or chronic myelogenous leukemia blastic crisis.
Raanani P; Trakhtenbrot L; Rechavi G; Rosenthal E; Avigdor A; Brok-Simoni F; Leiba M; Amariglio N; Nagler A; Ben-Bassat I
Acta Haematol; 2005; 113(3):181-9. PubMed ID: 15870488
[TBL] [Abstract][Full Text] [Related]
45. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
Egan DN; Beppu L; Radich JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870
[TBL] [Abstract][Full Text] [Related]
46. [Gene of DNA-dependent protein kinase catalylic subunit in chronic myeloid leukemia].
Luo J; Peng ZG; Chen Y; Lai YR; Lu YY; Song SJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):248-52. PubMed ID: 17493325
[TBL] [Abstract][Full Text] [Related]
47. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.
Bartholomeusz GA; Talpaz M; Kapuria V; Kong LY; Wang S; Estrov Z; Priebe W; Wu J; Donato NJ
Blood; 2007 Apr; 109(8):3470-8. PubMed ID: 17202319
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
Cortes J; Kim DW; Raffoux E; Martinelli G; Ritchie E; Roy L; Coutre S; Corm S; Hamerschlak N; Tang JL; Hochhaus A; Khoury HJ; Brümmendorf TH; Michallet M; Rege-Cambrin G; Gambacorti-Passerini C; Radich JP; Ernst T; Zhu C; Van Tornout JM; Talpaz M
Leukemia; 2008 Dec; 22(12):2176-83. PubMed ID: 18754032
[TBL] [Abstract][Full Text] [Related]
49. Induction of molecular remission by donor peripheral blood leukocyte therapy in patients relapsing with extramedullary blastic phase chronic myeloid leukemia after allogeneic bone marrow transplantation.
Bashey A; Shepherd S; Frankel W; Wang-Rodriguez J; Cahill T; Chamberlain M; Mason JR; Ho AD; Corringham RE
Oncol Rep; 1998; 5(1):281-5. PubMed ID: 9458334
[TBL] [Abstract][Full Text] [Related]
50. Treatment of chronic myeloid leukemia with imatinib mesylate.
Ohno R
Int J Clin Oncol; 2006 Jun; 11(3):176-83. PubMed ID: 16850123
[TBL] [Abstract][Full Text] [Related]
51. Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis.
Hirose Y; Kiyoi H; Iwai M; Yokozawa T; Ito M; Naoe T
Int J Hematol; 2002 Nov; 76(4):349-53. PubMed ID: 12463599
[TBL] [Abstract][Full Text] [Related]
52. Late relapse after allogeneic bone marrow transplantation for Philadelphia-positive acute lymphoblastic leukaemia.
Mughal T; Morleda J; Goldman J
Acta Haematol; 1993; 89(3):149-51. PubMed ID: 8362603
[TBL] [Abstract][Full Text] [Related]
53. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Elmaagacli AH; Beelen DW; Schaefer UW
Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
[TBL] [Abstract][Full Text] [Related]
54. Chronic myelogenous leukemia presenting with central nervous system infiltration, successfully treated with central nervous system-directed chemotherapy followed by allogeneic stem cell transplantation.
Chiba A; Toya T; Mizuno H; Tokushige J; Nakamura F; Nakazaki K; Kurokawa M
Int J Hematol; 2018 Dec; 108(6):640-646. PubMed ID: 30078165
[TBL] [Abstract][Full Text] [Related]
55. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.
Chu S; McDonald T; Lin A; Chakraborty S; Huang Q; Snyder DS; Bhatia R
Blood; 2011 Nov; 118(20):5565-72. PubMed ID: 21931114
[TBL] [Abstract][Full Text] [Related]
56. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.
Roche-Lestienne C; Deluche L; Corm S; Tigaud I; Joha S; Philippe N; Geffroy S; Laï JL; Nicolini FE; Preudhomme C;
Blood; 2008 Apr; 111(7):3735-41. PubMed ID: 18202228
[TBL] [Abstract][Full Text] [Related]
57. Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia.
Staber PB; Brezinschek R; Linkesch W; Sill H; Neumeister P
Haematologica; 2003 Aug; 88(8):ECR29. PubMed ID: 12935988
[TBL] [Abstract][Full Text] [Related]
58. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
Nicolini FE; Basak GW; Kim DW; Olavarria E; Pinilla-Ibarz J; Apperley JF; Hughes T; Niederwieser D; Mauro MJ; Chuah C; Hochhaus A; Martinelli G; DerSarkissian M; Duh MS; McGarry LJ; Kantarjian HM; Cortes JE
Cancer; 2017 Aug; 123(15):2875-2880. PubMed ID: 28387926
[TBL] [Abstract][Full Text] [Related]
59. Very long survival in complete cytogenetic remission in an adolescent with lymphoid blast crisis of chronic myeloid leukemia after treatment with intensive ALL-directed chemotherapy combined with continuous imatinib.
Maschan A; Novichkova G; Miakova N; Persiantseva M
Pediatr Blood Cancer; 2016 Dec; 63(12):2243-2245. PubMed ID: 27434016
[TBL] [Abstract][Full Text] [Related]
60. Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib.
Savani BN; Srinivasan R; Espinoza-Delgado I; Dorrance C; Takahashi Y; Igarashi T; Rezvani K; Lundqvist A; Barrett AJ; Childs RW
Lancet Oncol; 2005 Oct; 6(10):809-12. PubMed ID: 16198987
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
